AstraZeneca, Merck finally grab a green light for rare-disease med Koselugo

AstraZeneca, Merck finally grab a green light for rare-disease med Koselugo
It’s been a long road for AstraZeneca’s selumitinib, but one that’s finally led to a green light for the British drugmaker and its partner, Merck & Co. The FDA approved the drug under the name Koselugo to treat inoperable tumors in children two years and older with the rare neurological disorder neurofibromatosis type 1.
Source: Fierce Pharma
AstraZeneca, Merck finally grab a green light for rare-disease med Koselugo